Komori
General Meetings of Shareholders4582SymBio Pharmaceuticals LimitedPharmaceuticals

Notice Regarding the Tabulation Results of the Exercise of Voting Rights at the 21st Annual General Meeting of Shareholders

At the 21st Annual General Meeting of Shareholders, all 4 proposals, including amendments to the Articles of Incorporation and the election of directors and directors who are Audit & Supervisory Committee Members, were approved as proposed. Approval rates for the individual proposals ranged from 90.61% to 93.23%.

Worth reading
61In focus
Scored from 3 of 4 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
93.23
Approval rate (%, minimum: 90.61%)
Wording
Definitive
How definitive the wording is.

Resolutions for the General Meeting of Shareholders

Annual (21st fiscal year)
2026
Mar 24
Date and time(start time: Not disclosed)
Matters for resolution4 items
  1. Partial Amendments to the Articles of Incorporation

  2. Election of 5 directors, excluding directors who are Audit & Supervisory Committee Members

  3. Election of 3 Directors who are Audit and Supervisory Committee Members

  4. Election of 1 Substitute Director who is an Audit and Supervisory Committee Member

Shareholder Proposal

No

A shareholder proposal is a resolution submitted by a shareholder, rather than by the company.
Director nominee9 candidates in total (5 for Proposal 2, 3 for Proposal 3 and 1 for Proposal 4). The numbers of newly appointed and outside candidates were not disclosed.
Resolutions for the General Meeting of Shareholders
ItemDetails
Type of shareholders' meetingAnnual (21st fiscal year)
Date and time24 March 2026 (start time: Not disclosed)
Matters for resolutionProposal No. 1: Partial Amendments to the Articles of Incorporation, Proposal No. 2: Election of 5 directors, excluding directors who are Audit & Supervisory Committee Members, Proposal No. 3: Election of 3 Directors who are Audit and Supervisory Committee Members, Proposal No. 4: Election of 1 Substitute Director who is an Audit and Supervisory Committee Member
Shareholder ProposalNo
Director nominee9 candidates in total (5 for Proposal 2, 3 for Proposal 3 and 1 for Proposal 4). The numbers of newly appointed and outside candidates were not disclosed.
Items this document does not state (1)
Percentage voting in favor

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Proposal 1 increases the total number of authorized shares to enable flexible financing in preparation for future business expansion. No separate reasons were stated for the other proposals.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Tabulation Results of the Exercise of Voting Rights at the 21st Annual General Meeting of Shareholders | SymBio Pharmaceuticals Limited (4582) timely disclosure | Komori